Primary HPV-DNA screening in women under 30 years of age: health technology assessment
Carmen Doris Garzón-OlivaresCarlos Fernando Grillo-ArdilaJairo Amaya-GuíoMaría Teresa VallejoLuz Amparo Diaz-CruzCarolina Fernández-MottaAlejandra Del Pilar Gomez-MottaAlina Tatiana BarreraLina Maria TrujilloCarlos Humberto Pérez-MorenoLuis Jairo Bonilla-OsmaRobinson Fernández-MercadoNéstor Augusto Giraldo-MéndezJorge Eduardo Caro-CaroAmparo Leonor Ramírez-CorredorDayanne Milecsy Rodríguez-HernádezPublished in: Revista colombiana de obstetricia y ginecologia (2022)
The use of HPV-DNA testing as a screening strategy in women under 30 years of age is a potentially efficacious and cost-effective intervention for Colombia. Future studies should focus on analyzing new screening technologies, with emphasis on the population under 30 years of age.
Keyphrases
- cervical cancer screening
- polycystic ovary syndrome
- circulating tumor
- high grade
- public health
- randomized controlled trial
- single molecule
- healthcare
- cell free
- pregnancy outcomes
- mental health
- type diabetes
- risk assessment
- health information
- adipose tissue
- pregnant women
- skeletal muscle
- nucleic acid
- clinical evaluation